• Login
View Item 
  • DASH Home
  • Faculty of Arts and Sciences
  • FAS Scholarly Articles
  • View Item
  • DASH Home
  • Faculty of Arts and Sciences
  • FAS Scholarly Articles
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Browse

All of DASH
  • Communities & Collections
  • By Issue Date
  • Author
  • Title
  • Keyword
  • FAS Department
This Collection
  • By Issue Date
  • Author
  • Title
  • Keyword
  • FAS Department

Submitters

  • Login
  • Quick submit
  • Waiver Generator

About

  • About DASH
  • DASH Stories
  • DASH FAQs
  • Accessibility
  • COVID-related Research
  • Terms of Use
  • Privacy Policy

Statistics

  • By Schools
  • By Collections
  • By Departments
  • By Items
  • By Country
  • By Authors

Ferristatin II Promotes Degradation of Transferrin Receptor-1 In Vitro and In Vivo

 
Thumbnail
View/Open
3720890.pdf (1.020Mb)
Author
Byrne, Shaina L.
Buckett, Peter D.
Kim, JonghanHARVARD
Luo, FloraHARVARD
Sanford, Jack
Chen, Juxing
Enns, Caroline
Wessling-Resnick, MarianneHARVARD
Published Version
https://doi.org/10.1371/journal.pone.0070199
Metadata
Show full item record
Citation
Byrne, Shaina L., Peter D. Buckett, Jonghan Kim, Flora Luo, Jack Sanford, Juxing Chen, Caroline Enns, and Marianne Wessling-Resnick. 2013. “Ferristatin II Promotes Degradation of Transferrin Receptor-1 In Vitro and In Vivo.” PLoS ONE 8 (7): e70199. doi:10.1371/journal.pone.0070199. http://dx.doi.org/10.1371/journal.pone.0070199.
Abstract
Previous studies have shown that the small molecule iron transport inhibitor ferristatin (NSC30611) acts by down-regulating transferrin receptor-1 (TfR1) via receptor degradation. In this investigation, we show that another small molecule, ferristatin II (NSC8679), acts in a similar manner to degrade the receptor through a nystatin-sensitive lipid raft pathway. Structural domains of the receptor necessary for interactions with the clathrin pathway do not appear to be necessary for ferristatin II induced degradation of TfR1. While TfR1 constitutively traffics through clathrin-mediated endocytosis, with or without ligand, the presence of Tf blocked ferristatin II induced degradation of TfR1. This effect of Tf was lost in a ligand binding receptor mutant G647A TfR1, suggesting that Tf binding to its receptor interferes with the drug’s activity. Rats treated with ferristatin II have lower TfR1 in liver. These effects are associated with reduced intestinal 59Fe uptake, lower serum iron and transferrin saturation, but no change in liver non-heme iron stores. The observed hypoferremia promoted by degradation of TfR1 by ferristatin II appears to be due to induced hepcidin gene expression.
Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3720890/pdf/
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:11717549

Collections
  • FAS Scholarly Articles [17574]
  • HMS Scholarly Articles [17301]
  • SPH Scholarly Articles [6270]

Contact administrator regarding this item (to report mistakes or request changes)

Follow us on TwitterFollow us on FacebookFollow us on Google+

e: osc@harvard.edu

t: +1 (617) 495 4089

f: +1 (617) 495 0370

© 2018 President and Fellows of Harvard College
  • DASH
  • ETDs@Harvard
  • Copyright First Responders
  • HOPE
  • Contact
  • Harvard Library
  • Harvard University